References
- Rossi ED, Pantanowitz L, Hornick JL. A worldwide journey of thyroid cancer incidence centered on tumour histology. Lancet Diabetes Endocrinol. 2021;9(4):193–194.
- Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
- Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the society of nuclear medicine and molecular imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461–470.
- Campennì A, Barbaro D, Guzzo M, et al. Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts. Endocrine. 2020;70(2):280–291.
- Giovanella L, Clark PM, Chiovato L, et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol. 2014;171(2): R33–R46.
- Giovanella L, Feldt-Rasmussen U, Verburg FA, et al. Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. Clin Chem Lab Med. 2015;53(9):1301–1314.
- Verburg FA, Luster M, Cupini C, et al Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid. 2013;23(10): 1211–1225.
- Verburg FA, Mäder U, Giovanella L, et al. Low or undetectable basal thyroglobulin levels obviate the need for neck ultrasound in differentiated thyroid cancer patients after total thyroidectomy and 131I ablation. Thyroid. 2018;28(6): 722–728.
- Giovanella L, Trimboli P, Verburg FA, et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2013;40(6):874–880.
- Spencer C, LoPresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):394–404.
- Park S, Jeon MJ, Oh H-S, et al. Changes in serum thyroglobulin levels after lobectomy in patients with low-risk papillary thyroid cancer. Thyroid. 2018;28(8):997–1003.
- Ritter A, Mizrachi A, Bachar G, et al. Detecting recurrence following lobectomy for thyroid cancer: role of thyroglobulin and thyroglobulin antibodies. J Clin Endocrinol Metab. 2020;105(6):e2145–e2151.
- Xu S, Huang H, Zhang X, et al. Predictive value of serum thyroglobulin for structural recurrence following lobectomy for papillary thyroid carcinoma. Thyroid. 2021;31(9):1391–1399.
- Grani G, Lamartina L, Alfò M, et al. Selective use of radioactive iodine therapy for papillary thyroid cancers with low or lower-intermediate recurrence risk. J Clin Endocrinol Metab. 2021;106(4):e1717–e1727.
- Clerc J, Verburg FA, Avram AM, et al. Radioiodine after surgery for differentiated thyroid cancer: a reasonable option. Eur J Nucl Med Mol Imaging. 2017;44(6):918–925.